Cost‐effectiveness of investing in earlier access to diabetic foot services: A multi‐centre pre‐post study
Authors' conclusion
We found investing in earlier access to DFS to be cost-effective and generated considerably improved patient outcomes, cost savings, and return on investment.
Study context
- Population
- Patients with diabetes-related foot disease, 15 regions in Queensland, Australia
- Participants
- 1,687 patients
- Comparison
- Earlier access to new diabetic foot services (DFS) vs usual access to ambulatory DFS
- Interventionn = 857
- Controlsn = 830reference
- Outcome
- Cost, QALYs and clinical outcomes (cost-effectiveness)
- Follow-up
- 5-year time horizon
Methodological detailsgeneralised linear model, Bayesian Markov model, 7 health states, 5-year time horizon, Australian health service perspective
- Generalised linear model
- Bayesian Markov model
- 7 health states
- 5-year time horizon
- Australian health service perspective
Main finding
As reported in the abstract
Difference in costs
-$8429
95% CI -$8461, -$8397
reduced costs with intervention
Difference in quality-adjusted life year (QALYs)
0.06 QALYs
95% CI 0.05–0.07
increased QALYs with intervention
- Return per $AU1 invested in the intervention
- $AU7.86 [$7.63, $8.09]
Further findings
- Lower projected probability of hospitalisation with intervention vs controls, particularly after 20 months
Original publication
Cost‐effectiveness of investing in earlier access to diabetic foot services: A multi‐centre pre‐post study. Diabet Med. Published 26 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →